|
Real-time Estimate
Cboe BZX
20:54:17 30/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 86.78 USD | -0.37% |
|
+0.83% | +9.09% |
| 09-29 | Medicare Advantage premiums expected to drop more than 16% in 2027, CMS projects | RE |
| 09-24 | AI tools generated nearly $1 billion in extra costs, Blue Cross insurers say | RE |
| Market Cap | 111B 98.1B 92.94B 83.91B 158B 10,681B 160B 1,112B 428B 5,460B 418B 409B 17,506B | P/E 2026 * |
12.7x | P/E 2027 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise Value | 163B 144B 136B 123B 232B 15,656B 235B 1,630B 627B 8,004B 613B 600B 25,661B | EV / Sales 2026 * |
0.39x | EV / Sales 2027 * | 0.37x |
| Free-Float |
71.17% | Yield 2026 * |
3.05% | Yield 2027 * | 3.14% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
London S.E.
| 0HRS | Delayed | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Xetra
| CVS | Delayed | |
|
CBOE
| Real-time | ||
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
Swiss Exchange
| CVS | Delayed | |
|
CBOE
| 0HRS | Real-time | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | -0.44% | ||
| 1 week | +0.83% | ||
| Current month | -7.82% | ||
| 1 month | -7.82% | ||
| 3 months | -16.32% | ||
| 6 months | +23.42% | ||
| Current year | +9.09% |
| 1 week | 84.5 |  | 90.02 |
| 1 month | 84.5 | | 98.5 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 17/10/2024 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 01/03/2007 |
Anne Finucane
BRD | Director/Board Member | 73 | 20/01/2011 |
| Director/Board Member | 71 | 05/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/05/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 31/05/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 21/05/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.37% | +0.83% | +14.83% | +24.22% | 111B | |
| -0.26% | -1.22% | +1.16% | +74.41% | 93.45B | |
| +2.55% | +8.30% | +162.92% | +868.90% | 59.75B | |
| +1.21% | -3.01% | -4.88% | +50.03% | 28.21B | |
| +2.00% | +1.21% | +23.74% | +95.03% | 25.6B | |
| +0.21% | +1.80% | +7.80% | +55.06% | 25.04B | |
| -0.22% | +0.53% | +26.97% | +289.60% | 20.74B | |
| +3.24% | -0.44% | -14.53% | -3.86% | 20.45B | |
| -0.51% | -2.12% | +3.71% | +33.85% | 17.03B | |
| +0.67% | -0.92% | -10.29% | +51.67% | 15.61B | |
| Average | +0.82% | -1.12% | +21.14% | +153.89% | 41.73B | |
| Weighted average by Cap. | +0.54% | -0.30% | +29.54% | +177.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 368B 349B 315B 593B 40,060B 601B 4,171B 1,605B 20,480B 1,569B 1,535B 65,658B | 430B 379B 359B 324B 610B 41,220B 618B 4,291B 1,651B 21,073B 1,614B 1,579B 67,559B |
| Net income | 8.87B 7.82B 7.4B 6.68B 12.6B 851B 12.76B 88.59B 34.09B 435B 33.33B 32.6B 1,395B | 9.32B 8.21B 7.78B 7.02B 13.23B 894B 13.4B 93.02B 35.8B 457B 34.99B 34.23B 1,464B |
| Net Debt | 51.89B 45.69B 43.29B 39.08B 73.66B 4,975B 74.62B 518B 199B 2,543B 195B 191B 8,154B | 48.85B 43.01B 40.75B 36.79B 69.34B 4,683B 70.24B 488B 188B 2,394B 183B 179B 7,676B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/09/26 | $86.58 | -0.60% | 2,541,271 |
| 29/09/26 | $87.10 | -0.85% | 7,152,450 |
| 28/09/26 | $87.85 | -1.44% | 7,900,436 |
| 25/09/26 | $89.13 | +4.80% | 15,768,142 |
| 24/09/26 | $85.05 | -0.94% | 7,382,819 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
